Author: admin

Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034

Neurogenic Detrusor Overactivity Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Neurogenic Detrusor Overactivity Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Neurogenic Detrusor Overactivity Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Neurogenic Detrusor Overactivity, historical and forecasted epidemiology as well as the Neurogenic Detrusor Overactivity market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Neurogenic Detrusor Overactivity Market by downloading the comprehensive report from DelveInsight @ Neurogenic Detrusor Overactivity Market

 

Key Takeaways from the Neurogenic Detrusor Overactivity Market Report

  • The growth of the Neurogenic Detrusor Overactivity Market is expected to be primarily driven by increasing prevalence, increasing awareness, and improved diagnosis along with anticipated approval of emerging therapies.
  • In September 2024:- Astellas Pharma- A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-Release Microgranula-Based Suspension in Children From 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity.
  • In September 2024:- EG 427- First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants with Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization.
  • Neurogenic Detrusor Overactivity is estimated to affect 50–90% of patients with multiple sclerosis and 70–84% of patients with SCI.
  • Neurogenic Detrusor Overactivity in children can be caused by various conditions, including transverse myelitis, spinal cord injury, and spina bifida. Spina bifida is the most common cause, affecting 1,500–2,000 of the over 4 million babies born annually in the US.
  • It was found that the prevalence of urinary incontinence was 50.9% in patients with MS, 52.3% with SCI, 33.1% with Parkinson’s disease, and 23.6% with stroke.
  • The prevalence of urinary symptoms in patients with Parkinson’s disease was found to be nearly3% for detrusor hyperreflexia with detrusor-sphincter dyssynergia in Japan.
  • The prevalence of detrusor hyperreflexia in patients with Parkinson’s disease was found to be approximately 7.7% in Italy.
  • The leading Neurogenic Detrusor Overactivity Companies such as Astellas Pharma Inc., RECORDATI GROUP, Taris Biomedical LLC, Urovant Sciences GmbH, ethica Clinical Research Inc., Pfizer, GlaxoSmithKline, Ipsen, Allergan, Boehringer Ingelheim, Watson Pharmaceuticals, AbbVie, and others.
  • Promising Neurogenic Detrusor Overactivity Therapies such as Mirabegron, Vibegron, EG110A, and others.

 

Gain a competitive edge in the Neurogenic Detrusor Overactivity Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Neurogenic Detrusor Overactivity Treatment Drugs

 

Neurogenic Detrusor Overactivity Epidemiology Segmentation in the 7MM

  • Total Neurogenic Detrusor Overactivity Prevalent Cases
  • Total Neurogenic Detrusor Overactivity Diagnosed Prevalent Cases
  • Neurogenic Detrusor Overactivity Condition-specific Diagnosed Prevalent Cases
  • Neurogenic Detrusor Overactivity Treated Cases

 

Neurogenic Detrusor Overactivity Market Insights

The primary management of NDO focuses on behavioral approaches, such as increasing the frequency of urination, reducing fluid intake in the evening, avoiding diuretics like caffeine and alcohol, and using absorbent undergarments or bed pads. Pharmacologic treatments are the next step in managing NDO. Anticholinergic medications are commonly used, as they reduce detrusor muscle activation by blocking cholinergic muscarinic receptors. These drugs are available in both oral and transdermal forms, but they are nonspecific and can cause systemic side effects such as dry eyes, dry mouth, and visual disturbances due to ciliary muscle paralysis. Gastrointestinal effects like reduced motility and secretion can result in halitosis, dental caries, and constipation. Additionally, anticholinergic therapy may decrease sweating, which can be particularly problematic for multiple sclerosis patients who already experience heat intolerance.

 

Discover key developments and opportunities in the Neurogenic Detrusor Overactivity Market. Click here to learn more from DelveInsight’s latest report @ Neurogenic Detrusor Overactivity Market Size

 

Neurogenic Detrusor Overactivity Drugs Uptake

  • DYSPORT (abobotulinumtoxinA) is an injectable form of a botulinum neurotoxin type A (BoNT-A) product, which is a substance derived from Clostridium bacteria producing BoNT-A that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. DYSPORT is approved for the management of urinary incontinence in adults with NDO due to SCI or multiple sclerosis in multiple countries including the UK and others.
  • BOTOX is a neuromuscular blocking agent and acetylcholine release inhibitor used for managing neurogenic detrusor overactivity (NDO) in pediatric patients aged 5 years and older who do not respond adequately to or are intolerant of anticholinergic medications. It is the first neurotoxin approved specifically for this indication.
  • MYRBETRIQ (mirabegron extended-release tablets) and MYRBETRIQ S (mirabegron extended-release oral suspension granules) are beta-3 adrenergic agonists indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older in the US. Additionally, mirabegron is marketed under the brand name BETMIGA for the treatment of NDO.

 

Neurogenic Detrusor Overactivity Emerging Drugs Profile

  • EG110A: EG 427

EG110A is a recombinant herpes simplex virus type 1 (HSV-1)-derived vector that does not replicate and expresses the light chain of botulinum neurotoxin F (BoNT/F-LC) under the control of the human calcitonin gene-related peptide (hCGRP) promoter. It is designed to provide long-term, sensory neuron-selective transgenic expression in bladder afferents. 

 

Download DelveInsight’s Neurogenic Detrusor Overactivity Market report today and stay ahead in this rapidly evolving field. @ Neurogenic Detrusor Overactivity Clinical Trials

 

Scope of the Neurogenic Detrusor Overactivity Market Report

  • Coverage- 7MM
  • Neurogenic Detrusor Overactivity Companies- Astellas Pharma Inc., RECORDATI GROUP, Taris Biomedical LLC, Urovant Sciences GmbH, ethica Clinical Research Inc., Pfizer, GlaxoSmithKline, Ipsen, Allergan, Boehringer Ingelheim, Watson Pharmaceuticals, AbbVie, and others.
  • Neurogenic Detrusor Overactivity Therapies- Mirabegron, Vibegron, EG110A, and others.
  • Neurogenic Detrusor Overactivity Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Neurogenic Detrusor Overactivity Unmet Needs, KOL’s views, Analyst’s views, Neurogenic Detrusor Overactivity Market Access and Reimbursement

 

Download the report to understand which factors are driving Neurogenic Detrusor Overactivity Market Trends @ Neurogenic Detrusor Overactivity Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Neurogenic Detrusor Overactivity

3. Competitive Intelligence Analysis for Neurogenic Detrusor Overactivity

4. Neurogenic Detrusor Overactivity: Market Overview at a Glance

5. Neurogenic Detrusor Overactivity: Disease Background and Overview

6. Patient Journey

7. Neurogenic Detrusor Overactivity Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Neurogenic Detrusor Overactivity Unmet Needs

10. Key Endpoints of Neurogenic Detrusor Overactivity Treatment

11. Neurogenic Detrusor Overactivity Marketed Products

12. Neurogenic Detrusor Overactivity Emerging Therapies

13. Neurogenic Detrusor Overactivity: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Neurogenic Detrusor Overactivity

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034

New Book Release: Extreme Nazarene: Present Day Saints and Soldiers by Adam P Childress, M.A.O.M.

New Book Release: Extreme Nazarene: Present Day Saints and Soldiers by Adam P Childress, M.A.O.M.

In a world fraught with spiritual challenges and moral dilemmas, author Adam P Childress, M.A.O.M., releases his groundbreaking new book, Extreme Nazarene: Present Day Saints and Soldiers. This powerful work calls Christians to rise as spiritual warriors, equipped to face the battles of our time with unwavering faith and purpose.

Extreme Nazarene addresses the urgent need for a renewed sense of mission among Christians today. Childress draws on his extensive personal experiences, including his time in the military and his academic background, to offer a unique perspective on how to embody the role of Christ’s soldiers in the modern world. The book guides readers through the process of recognizing their spiritual mission and provides practical advice on how to prepare for and engage in the spiritual warfare that all believers inevitably face.

Childress’s book is more than just a call to arms; it is a comprehensive guide to spiritual resilience. Through a series of insightful chapters, he explores the importance of returning to the basics of the Christian faith, much like soldiers returning to their basic training. By relating the teachings of the Bible to military principles, Extreme Nazarene offers a structured approach to developing a strong spiritual foundation. This foundation, Childress argues, is essential for Christians to effectively communicate the love of Christ in their private lives, professional environments, and public interactions.

Childress also delves into the importance of Christian fellowship and the power of unity among believers. He emphasizes that, just as in any military force, success in spiritual warfare is not achieved in isolation. Rather, it requires a strong sense of community and mutual support among those who share the same faith. His writing encourages readers to build and nurture these connections, reinforcing the idea that Christians are part of the greatest spiritual military ever assembled on Earth.

Extreme Nazarene: Present Day Saints and Soldiers is available now on Amazon and other major book retailers. It is an essential read for anyone seeking to deepen their faith, strengthen their resolve, and stand firm in the face of spiritual opposition. As the world continues to grow more complex and challenging, Childress’s book serves as a timely reminder that, with the right preparation and mindset, every Christian can rise to the occasion as a true soldier of Christ.

About the Author

Born in 1966 in Harvey, Illinois (South Chicago). That very year, my mother, sister, and I were caught in the blizzard of 1966 in Chicago. We would have starved to death if my mother had not used serious survival skills to make pancakes out of flour and water for months. That was a close call. My parents’ marriage was hitting major lows. My father, who spent three tours in Vietnam, was by this time quite a different person altogether. After some brutal encounters, my parents split. What a beginning! We, my older sister and baby brother entered the foster care system.

Later, we were pawned off to a more permanent foster family. Life was not the same in this foster home. After two and a half years of sexual, physical, and mental abuse, we were a mess. While living at the foster home, I learned to work hard and long hours.

In the meantime, our little minds were shutting down, and we ate like animals. We did not use forks, knives, or spoons all the time. We ate with our hands. Some days, we acted totally normal, and other days like a wild pack of dogs. After a time, the state gave us a battery aptitude test to evaluate us. I was certified as mentally retarded. Now, the abuse stepped up a notch. The “retarded boy” did not understand what was going on. (I do want to make something completely clear: the foster parents had nothing to do with the sexual abuse.)

My grandfather, who resided in Italy, had written letters several years later to every state senator and congressman in America. Finally, the battle for the three children began. By 1976, my grandfather, my mother, and her new soon-to-be-husband won the battle. Praise God. Finally, we loaded up in the brand-new Grand Prix they showed up in and headed to Colorado Springs, Colorado. A new family I began to watch days turn into months and then years.

I began to smarten up. I watched as, time after time, my brothers would brutally speak words of hate. They would defy their father and mother. I realized I did not want to cause any more pain, shame, or fear to my family. I stayed out of trouble as best as a curious boy could. I began focusing on how to help myself in this life. I went to church off and on. I was not really committed but interested in the girls, food, and fun. I began mowing grass and washing cars. It kept me busy and out of trouble. It even made my parents happy. I stuttered a little when I spoke and was extremely fearful of having to explain a mistake. I had no confidence in myself.

We were moving again, this time to Las Vegas, Nevada. Seventh grade in Las Vegas was like being sent to prison every school day. I was sure someone was going to kill me just because I was slow to speak. All you had to say was boo, it would have made me pee my pants. Eighth grade was a little different. I guess I started getting better looking. I had a lot of attention from the girls. This made me popular and a target for the local school gangs. Here is where I learned to put my hidden talent to work. I found out that fighting back meant respect. So, I began protecting myself and anyone who could not.

High school quickly approached, and home life sucked big time. Our family had been torn to shreds by everyone’s horrible behavior. My freshman year in high school was smooth. I saw seniors roughing up freshmen all around me, but no one was pushing me around. Maybe I did not look like a freshman. I played football and was on the wrestling team. My sophomore year was just about the same.

I began to work a job full time. In my junior year, I did not go out for football or wrestling. I began to get bored with it. I was barely passing my classes during ninth and tenth grades. The eleventh grade quickly went by. I would party all night long. I went to school and worked a full-time job. After work it was straight to the clubs to drink and dance. Senior year came and parties were nonstop.

The school was a roller coaster ride. I missed so many days the principal threatened to not let me graduate! I had been awarded a scholarship to UNLV for vocal music. Things were looking up. My girlfriend’s parents moved to a nearby town called Pahrump. In Pahrump, I had gotten involved in shady dealings and almost had gotten shot. I never did collect on the scholarship. I soon realized the path I was on was going to lead me straight to the grave or prison. I thought long and hard about my life. I was 18 and a new believer in Jesus Christ. I knew if I did not change my behavior, I would never make it alive. I decided to join the U.S. Army. Joining the Army was one of the best decisions I would ever make. Eventually, I was recruited by a clandestine group and began participating in special intelligence operations. I was privileged to have traveled over sixty countries while serving in United States Army.

Book Name: Extreme Nazarene

Author Name: Adam P Childress, M.A.O.M

ISBN Number: 979-8330252817

Kindle Version: Click Here

Paperback Version: Click Here

Hardcover Version: Click Here

Media Contact
Company Name: Book Publishing Pros
Email: Send Email
Phone: +1-213-734-5715
Address:17595 Harvard Ave, Ste C-641
City: Irvine
State: California
Country: United States
Website: https://bookpublishingpros.co

Greece Data Center Colocation Market to Reach $125 Million by 2029, Greece Attracts Major Cloud Investments, Establishing Itself as a Key Computing Hub – Arizton

“Greece Data Center Colocation Market Research Report”
Get Insights on 15 Existing Colocation Data Center Facilities and 03 Upcoming Facilities across Greece.

  

According to Arizton’s latest research report, the Greece data center colocation market is growing at a CAGR of 14.32% during 2023-2029.

     

Looking for More Information? Click: https://www.arizton.com/market-reports/greece-data-center-colocation-market

 

Report Scope:     

Market Size (Colocation Revenue): USD 125 Million (2029) 

Market Size (Utilized White Floor Area): 290 thousand Sq. Ft. (2029) 

Market Size (Utilized Racks): 9 thousand Units (2029) 

Market Size (Utilized IT Power Capacity): 57 MW (2029) 

Base Year: 2023 

Forecast Year: 2024-2029 

      

Book the Free Sample Now: https://www.arizton.com/market-reports/greece-data-center-colocation-market

 

In Greece, colocation operators added over 184,000 square feet of core and shell white floor area, with approximately 80,110 square feet actively utilized, reflecting a utilization rate of more than 40%. According to Turner & Townsend’s Data Center Cost Index, the core and shell development costs for data centers in Athens range from $6.5 to $7.0 per watt, notably lower than costs in other major European markets like Frankfurt, London, Amsterdam, Paris, and Dublin.

Major players in the Greek data center market include Telecom Italia Sparkle, Digital Realty (Lamda Helix), Lancom, and Synapsecom Telecoms, all contributing to the expansion of data center facilities, which is expected to increase the white floor area in the coming years. Additionally, Greece offers four free trade zones—located in Thessaloniki, Piraeus, Heraklion, and Astakos Aitoloakarnanias—providing investors with significant incentives, such as a 100% corporate tax exemption and full customs duty exemption.

 

Greece Emerges as a Cloud Computing Hub with Major  Investments

Since the implementation of Greece’s cloud-first policy in September 2020, the country has attracted top cloud providers like AWS, Microsoft, and Google, enhancing user experience, reducing costs, and positioning Greece as a growing center for cloud computing.

In September 2023, Google Cloud expanded its global infrastructure by launching a new region in Athens, further advancing the nation’s digital capabilities. This moves underscores Google’s commitment to sustainability, with goals to achieve net-zero emissions by 2030.

Additionally, the Greek government is actively promoting cloud investments through initiatives like the Innovation and Entrepreneurship Fund (INNOVATHENS), which provides grants and support to startups and small businesses developing innovative cloud-based solutions.

 

What’s Included?

  • Transparent research methodology and insights on the market’s colocation of demand and supply.
  • Market size is available in terms of utilized white floor area, IT power capacity, and racks.
  • Market size available in terms of Core & Shell Vs Installed Vs Utilized IT Power Capacity along with the occupancy %.
  • An assessment and snapshot of the colocation investment regarding core & shell area, power, and rack in Greece and a comparison between Nordic countries.
  • The study of the existing Greece data center industry landscape and insightful predictions about industry size during the forecast period.
  • An analysis of the current and future colocation demand in Greece by several industries. 
  • Study on sustainability status in the region
  • Analysis of current and future cloud operations in the region.
  • Snapshot of upcoming submarine cables and existing cloud-on-ramps services in the region.
  • Snapshot of existing and upcoming third-party data center facilities in Greece
    • Facilities Covered (Existing): 15
    • Facilities Identified (Upcoming): 03
    • Coverage: 4+ locations
    • Existing vs. Upcoming (White Floor Area)
    • Existing vs. Upcoming (IT Load Capacity)
    • Data Center Colocation Market in Greece
      • Colocation Market Revenue & Forecast (2023-2029)
      • Retail Colocation Revenue (2023-2029)
      • Retail Colocation Pricing along with Addons
      • An analysis of the latest trends, potential opportunities, growth restraints, and prospects for the Greece data center colocation market.
      • Competitive landscape, including industry share analysis by the colocation operators based on IT power capacity and revenue.
      • The vendor landscape of each existing and upcoming colocation operator is based on the existing/ upcoming count of data centers, white floor area, IT power capacity, and data center location.

 

The Report Includes:

  • Colocation Supply (MW, Area, Rack Capacity)
  • Colocation Demand (MW, Area, Rack Capacity) and by End-User (Cloud/IT, BFSI, .)
  • Colocation Revenue (Retail & Wholesale Colocation Services)
  • Competitive Scenario (Share Analysis by Revenue & MW Capacity)

 

Vendor Landscape

Existing Colocation Operators

  • CloudRock
  • Digital Realty (Lamda Hellix)
  • Friktoria
  • Hostmein IKE
  • Telecom Italia Sparkle
  • Lancom
  • Synapsecom Telecoms

 

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4507

     

Key Questions Answered in the Report:     

What is the count of existing and upcoming colocation data center facilities in Greece?

What factors are driving Greece data center colocation market?

How much MW of IT power capacity is likely to be utilized in Greece by 2029?

   

Check Out Some of the Top Selling Research Reports:   

Greece Data Center Market – Investment Analysis & Growth Opportunities 2024-2029

The Greece data center market will witness cumulative investments of over USD 1.34 billion by 2029, growing at a CAGR of 9.91% during the forecast period. Explore! https://www.arizton.com/market-reports/greece-data-center-market

Sweden Data Center Colocation Market – Supply & Demand Analysis 2024-2029

The Sweden data center colocation market size was valued at USD 210 million in 2023 and is expected to reach USD 525 million by 2029, growing at a CAGR of 16.50% during the forecast period. Explore! https://www.arizton.com/market-reports/sweden-data-center-colocation-market

 

Why Arizton?                                              

100% Customer Satisfaction                                              

24×7 availability – we are always there when you need us                                              

200+ Fortune 500 Companies trust Arizton’s report                                              

80% of our reports are exclusive and first in the industry                                              

100% more data and analysis                                              

1500+ reports published till date                            

                 

Post-Purchase Benefit                                          

  • 1hr of free analyst discussion                                          
  • 10% off on customization                       

                

About Us:                                                                                   

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                 

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                  

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                      

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707    
Country: United States
Website: https://www.arizton.com/market-reports/greece-data-center-colocation-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Greece Data Center Colocation Market to Reach $125 Million by 2029, Greece Attracts Major Cloud Investments, Establishing Itself as a Key Computing Hub – Arizton

Cell Culture Market Size: Set to Reach USD 46.22 Billion by 2031| SkyQuest Technology

“Cell Culture Market”
Cell Culture Market to Reach $46.22B by 2031, Growing at a Significant CAGR | Top Companies: Becton, Dickinson and Company, Corning Incorporated, Eppendorf

Cell Culture Market is a crucial sector belonging to life sciences and biotechnology. It emphasizes cultivating cells under special controlled conditions for drug development, research, and several therapeutic applications. The market is notably driven by technological advancements and modernizations in cell culture techniques. Moreover, the growing cases of chronic illnesses and mounting demand for personalized medicine are further impacting the growth of the market. This also includes the growth and progress made by regenerative medicine stem cell research. These factors altogether are propelling the cell culture market.

The latest trends in cell culture reflect improvements in research, technology, and its applications. Automation technologies are actively being incorporated in different cell culture processes. Automated systems for cell seeding, media preparation, and monitoring significantly decrease human error, improve efficiency and enhance reproducibility. This ultimately streamlines workflows, reduces labor costs and enhances overall throughput. Besides, cell culture is also being used in the development of organoids. Organoids are reduced or miniaturized, in simpler forms of organs developed from stem cells. They are used in the study of drug responses, disease mechanism, and development of tissues. They facilitate regenerative therapies, personalized medicine by offering models that imitate human organ functioning.

Get a Free Sample Research Report:https://www.skyquestt.com/sample-request/cell-culture-market

 

Segmental Analysis:

By Product Consumables, Sera, Media, Reagents, Bioreactor Accessories, Instruments, Bioreactors, Cell Culture Vessels, Cell Culture Storage Equipment, Cell Culture Supporting Instruments

By Application Stem Cell Technology, Cancer Research, Drug Screening and Development, Tissue Engineering & Regenerative Medicine, Others

By End User Research Institutes, Pharmaceutical & Biotechnology Companies, Others

By Region North America, U.S., Canada, Mexico, Europe, Germany, UK, Italy, France, Spain, Rest of Europe, Asia-Pacific, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific, LAMEA, Brazil, Saudi Arabia, Rest of LAMEA

 

Improvements in Single-Cell Analysis to Spur Market Growth in FutureThere have been several advances made in single-cell RNA sequencing, which helps in the study of gene expression at patient-level, enlightening fine details and cell heterogeneity of cellular procedures. This helps in the better understanding of cancer biology, complex tissues, and immune responses and aids in the progress of targeted therapies. The market is also witnessing the development of novel cell culture media. Improved and novel media supplements and formulations improve the viability, growth, and productivity of different types of cells, comprising complex stem and primary cells. Furthermore, research teams can now effectively customize media compositions to certain forms or trial needs. This enhances experimental reproducibility and results. These improvements reflect a wider range of modernizations in cell culture, impacted by the growing need for highly accurate models, personalized medicine, and scalable production systems.

  • In April 2024, Becton, Dickinson and Company announced the commercial supply of novel cell sorters. These sorters will allow more researchers in wider domains, comprising immunology and cancer research, cell biology, and more to unveil insights not visible previously in conventional cytometry trials.
  • In February 2023, Corning Life Sciences to present a package of 3D culture technologies, comprising the novel Elplasia® 12K flask and Elplasia plate (soon-to-be-unveiled) with an open-well set-up to enable organoid and spheroid manipulations. 
  • In July 2023, Sartorius recently added cell culture media manufacturing building to its current facility in Yauco. The recently unveiled facility of 21,500 square feet will expand Sartorius’s capacities for cell culture.
  • In July 2023, Merck declared Euro 23 million investment to increase its production of cell culture media in Lenexa Kansas. This comprises 9,100 square foot m2 of extra production space and re-designed laboratory space. The investment will also create employment for people in Kansas City.

 

Ask for Customization:https://www.skyquestt.com/speak-with-analyst/cell-culture-market

 

 

The report covers the following players: 

  • Becton, Dickinson and Company
  • Corning Incorporated
  • Eppendorf
  • Sartorius AG
  • Merck KGaA
  • Lonza Group AG
  • PromoCell GmbH
  • Danaher Corporation
  • Thermo Fisher Scientific
  • HiMedia Laboratories
  • Agilent
  • Eppendorf AG

 

This report covers the following segments:  

  1. A. Product
  2. Consumables
  3. Sera
  4. Media
  5. Reagents
  6. Bioreactor Accessories
  7. Instruments
  8. Bioreactors
  9. Cell Culture Vessels
  10. Cell Culture Storage Equipment
  11. Cell Culture Supporting Instruments
  13. B. Application
  14. Stem Cell Technology
  15. Cancer Research
  16. Drug Screening and Development
  17. Tissue Engineering & Regenerative Medicine
  18. Others
  20. C. End-User
  21. Research Institutes
  22. Pharmaceutical & Biotechnology Companies
  23. Others

 

View report summary and Table of Contents (TOC):https://www.skyquestt.com/report/cell-culture-market

 

Development of 3D Culture Models and Organoids to Fuel Better Growth of CellsIn conclusion, the latest trends in cell culture highlight major advancements that are transforming the future of medical research and biotechnology. The major developments comprise the growth of organoids and 3D culture models that deliver precision in simulations of in-vivo conditions. The incorporation of AI and automated systems improves data analysis and efficiency and enhances bioreactor and in-cell culture technologies that aid superior quality and scalable growth of cells.

 

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/cell-culture-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cell Culture Market Size: Set to Reach USD 46.22 Billion by 2031| SkyQuest Technology

Hepatocellular Carcinoma Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

DelveInsight’s, “Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Hepatocellular Carcinoma Research. Learn more about our innovative pipeline today! @ Hepatocellular Carcinoma Pipeline Outlook

 

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

  • In September 2024:- Translational Research in Oncology- A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria
  • In September 2024:- Hoffmann-La Roche- This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.
  • In September 2024:- Akeso- The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial.
  • DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
  • The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
  • Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others

 

Stay informed about the cutting-edge advancements in Hepatocellular Carcinoma Treatments. Download for updates and be a part of the revolution in cancer care @ Hepatocellular Carcinoma Clinical Trials Assessment

 

Hepatocellular Carcinoma Emerging Drugs

 

  • Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Liver Cancer and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.

  • SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.

  • Porustobart: Harbour BioMed

Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

  • Fisogatinib: CStone Pharmaceuticals

Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.

  • STP705: Sirnaomics

STP705 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-β1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various liver cancers. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.

 

Learn more about Hepatocellular Carcinoma Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ Hepatocellular Carcinoma Unmet Needs

 

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

 

Scope of the Hepatocellular Carcinoma Pipeline Report

  • Coverage- Global
  • Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
  • Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others
  • Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Hepatocellular Carcinoma Pipeline on our website @ Hepatocellular Carcinoma Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatocellular Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Namodenoson: Can-Fite BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SRF388: Surface Oncology
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. STP705: Sirnaomics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Hepatocellular Carcinoma Key Companies
  21. Hepatocellular Carcinoma Key Products
  22. Hepatocellular Carcinoma- Unmet Needs
  23. Hepatocellular Carcinoma- Market Drivers and Barriers
  24. Hepatocellular Carcinoma- Future Perspectives and Conclusion
  25. Hepatocellular Carcinoma Analyst Views
  26. Hepatocellular Carcinoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

Ogden Deck Depot Named Best Lumber Yard in Ogden, Utah

Ogden Deck Depot Named Best Lumber Yard in Ogden, Utah

Ogden Deck Depot Logo
Lumber Yard at Ogden Deck Depot

Ogden, Utah – September 20, 2024 – Ogden Deck Depot is proud to announce its recent recognition as the best lumber yard in Ogden, Utah. This award highlights Ogden Deck Depot’s dedication to providing top-quality lumber yard services and its commitment to serving the local community with the finest deck lumber and building materials. Specializing in high-quality lumber and exceptional customer service, Ogden Deck Depot has become the go-to destination for homeowners, contractors, and builders looking for reliable lumber solutions.

Ogden Deck Depot has earned its reputation by offering a wide range of lumber yard services that cater to the needs of DIY enthusiasts and professional builders alike. Whether you’re working on a custom deck, a home renovation, or a larger construction project, Ogden Deck Depot ensures you have access to the best materials available.

“We are honored to be recognized as the top lumber yard in Ogden,” said the Owner of Ogden Deck Depot. “Our focus has always been on providing our customers with the highest quality lumber, deck lumber, and materials, along with excellent service. This recognition reflects our team’s hard work and dedication to helping our community build and improve their outdoor spaces.”

Comprehensive Lumber Yard Services

Ogden Deck Depot is known for its extensive inventory and range of services, designed to meet the diverse needs of customers. From selecting the right type of lumber for your project to providing guidance on deck construction, the team at Ogden Deck Depot is committed to helping customers achieve their goals.

Their key offerings include:

  • Deck Lumber: A wide selection of high-quality deck lumber, including pressure-treated wood, cedar, and composite options, ensures durability and style for every deck project.

  • Framing and Structural Lumber: Premium lumber options for framing and structural needs, ideal for everything from residential construction to commercial projects.

  • Custom Lumber Orders: Personalized assistance for custom lumber orders to ensure you have the exact materials you need for any project, regardless of size or complexity.

  • Expert Guidance and Support: The team at Ogden Deck Depot offers knowledgeable advice to help you choose the best materials and lumber for your specific project. Their hands-on support ensures customers can confidently tackle any building task.


“Whether you’re looking for deck lumber or materials for a larger construction project, our team is here to guide you every step of the way,” said the Operations Manager at Ogden Deck Depot. “We understand how important it is to have the right materials, and we are committed to helping our customers succeed in their projects with the best lumber available.”

The Best Lumber for Deck Construction

Ogden Deck Depot specializes in providing deck lumber that meets the highest standards of quality and durability. Their extensive selection includes pressure-treated lumber, composite decking materials, and specialty wood products, ensuring that customers can find the perfect materials for their decks. With a focus on sustainable and long-lasting products, Ogden Deck Depot helps homeowners and contractors create outdoor spaces that are built to last.

Looking to the Future

As Ogden Deck Depot continues to serve as the premier lumber yard in Ogden, the company is dedicated to expanding its offerings and enhancing its customer experience. With plans to introduce new lumber products and services in the coming months, Ogden Deck Depot remains committed to being a trusted resource for all building and deck construction needs in Northern Utah.

To celebrate this recognition, Ogden Deck Depot will be hosting an open house, where customers can explore the lumber yard, meet the team, and take advantage of special promotions on deck lumber and other building materials. The event will feature product demonstrations, expert consultations, and exclusive discounts for attendees.

About Ogden Deck Depot

Ogden Deck Depot has been a trusted provider of lumber and building materials in Ogden, Utah, for years. With a focus on quality, customer satisfaction, and expert support, Ogden Deck Depot has established itself as the leading lumber yard in the region. Offering a comprehensive selection of deck lumber, framing materials, and custom orders, Ogden Deck Depot is the preferred choice for builders and homeowners looking for the best materials for their projects.

For more information, visit https://www.ogdendeckdepot.com/ or contact Ogden Deck Depot at (435) 222-5819 or ogdendecks@gmail.com.

Media Contact
Company Name: Ogden Deck Depot
Contact Person: AJ Van Dugteren
Email: Send Email
Phone: (435) 222-5819
Address:190 W 33rd Street #160
City: Ogden
State: Utah 84401
Country: United States
Website: www.ogdendeckdepot.com/

The Disc Chiropractic Launches Advanced Shockwave Therapy for Non-Invasive Pain Relief

The Disc Chiropractic Launches Advanced Shockwave Therapy for Non-Invasive Pain Relief

Lower Back Pain
The Disc Chiropractic introduces Shockwave Therapy, a non-invasive solution for chronic pain relief, using acoustic waves to accelerate healing. Effective for conditions like plantar fasciitis and shoulder tendinitis, the therapy offers quick recovery with minimal downtime and serves as a cost-effective alternative to surgery and medication. Combining this with X-ray diagnostics and spinal decompression, The Disc Chiropractic provides advanced, comprehensive care for patients seeking pain relief

Surprise, AZ – The Disc Chiropractic is excited to announce the launch of its newest service: Shockwave Therapy, an innovative, non-invasive treatment designed to provide effective pain relief for patients suffering from chronic musculoskeletal conditions. This cutting-edge technology delivers acoustic waves to target pain points and stimulate the body’s natural healing processes, offering a powerful alternative to surgery and medication.

Key Benefits of Shockwave Therapy:

  • Non-Invasive Pain Relief: Shockwave Therapy effectively addresses pain without the need for invasive surgery or long-term medication use, making it a safer alternative for patients.

  • Quick Recovery Times: Treatment sessions typically last around 15 minutes, with minimal downtime, allowing patients to return to their daily routines faster.

  • Effective for Chronic Conditions: This therapy has shown significant success in treating chronic conditions such as plantar fasciitis, shoulder tendinitis, and tennis elbow, improving both pain levels and mobility.

  • Cost-Effective: By reducing the need for expensive surgeries and medications, Shockwave Therapy offers a more affordable solution for long-term pain management.

The Disc Chiropractic is proud to introduce this advanced treatment, aligning with the industry’s shift toward more holistic and technologically advanced care options. “Our practice is dedicated to staying at the forefront of chiropractic care, and Shockwave Therapy exemplifies our commitment to offering modern, effective treatments,” said Dr. Al Simeone.

Setting Us Apart The Disc Chiropractic combines advanced technology with a personalized approach to patient care. Offering a unique combination of X-ray diagnostics, spinal decompression, and Shockwave Therapy, the practice provides comprehensive solutions for diagnosing and treating musculoskeletal issues, ensuring tailored and highly effective treatment plans.

For more information about Shockwave Therapy and other services offered by The Disc Chiropractic, visit https://thediscchiropractic.com/ or contact 7205734910.

Media Contact
Company Name: The Disc Chiropractic
Contact Person: Dr. Al Simeone
Email: Send Email
Phone: (720) 573-4910
Address:6990 W 38th Ave #205
City: Wheat Ridge
State: CO
Country: United States
Website: https://thediscchiropractic.com/

Mobile Apps and Web Analytics Market Size, Share, Future Trends, Growth Factors, Industry Analysis, Advance Technology And Forecast – 2027

“Microsoft (US), Google (US), Oracle (US), SAP (US), AWS, IBM (US), Teradata (US), Adobe (US), SAS Institute (US), Micro Focus (US), comScore (US), Salesforce (US), Splunk (US), Microstrategy (US), AT Internet (US), Webtrends (US), Tibco Software (US), Mixpanel (US), Upland Localytics (US), Amplitude Analytics (France), Qlik (US), Flurry (US), Cooldata (US), Countly (UK).”
Mobile Apps and Web Analytics Market by Component (Solutions & Services), Solution (Data Analytics, Data Discovery), Application (Content Marketing, Marketing Automation), Deployment Mode, Organization Size, Vertical and Region – Global Forecast to 2027.

The Mobile Apps and Web Analytics market is expected to grow from USD 9.4 billion in 2022 to USD 20.2 billion by 2027, with a compound annual growth rate (CAGR) of 16.4% over the forecast period. This practical domain integrates both traditional and modern disciplines to develop, model, align, execute, analyze, and refine decision-making models and operations. These analytics solutions leverage behavioral and operational insights to collect data on app performance and user behavior, providing actionable insights to enhance user experience, boost engagement, and improve overall reliability.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139197732  

Cloud segment to account for higher CAGR during the forecast period

The Mobile Apps and Web Analytics market is bifurcated on the basis of cloud and on-premises. The market size of the cloud deployment mode is estimated to be larger and projected to have a higher CAGR during the forecast period. The new means to access technology and the information a company needs to react rapidly to shifting markets and address business issues is made possible by cloud computing. It introduces a new technique for creating platforms, infrastructure, and services. Today’s business professional finds it harder than ever to find data-driven insights. Business customers typically receive static spreadsheets and presentations from analytical experts that are challenging to examine and manipulate.

SMEs segment to account for higher CAGR during the forecast period

The Mobile Apps and Web Analytics  market is bifurcated on the basis of large enterprises and SMEs. The CAGR of the SMEs is estimated to be highest during the forecast period. SMEs make up a vast majority of enterprises globally and play a significant role in most economies. Analytics-based data helps improve overall business intelligence and assists in making wise business decisions. Web analytics is crucial for businesses to identify and comprehend the target market. This information can be very helpful, especially if the business is global or is considering entering a new market. This, in turn, would enable SMEs to adopt mobile apps and web analytics platforms and services.

APAC to hold higher CAGR during the forecast period

Over the next five years, the Asia Pacific region is expected to witness the fastest growth in the Mobile Apps and Web Analytics market. SMEs and large enterprises in Asia Pacific have become more aware of government regulations and compliances and started adopting AI-based solutions proactively. The adoption of AI technology by different verticals, such as the BFSI, travel and hospitality, and retail, is expected to contribute to the high growth of the mobile apps & web analytics market. The growing eCommerce, online streaming, and increasing internet penetration have resulted in the growth of marketing industries. Marketers now look for more sophisticated marketing solutions for a large, ever-growing consumer base. This, in turn, has resulted in the adoption of AI-enabled solutions for marketing.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=139197732  

Unique Features in the Mobile Apps and Web Analytics Market

This rapid growth highlights the increasing importance of data-driven insights for businesses aiming to improve app functionality and user experience. A unique feature of this market is its ability to blend both traditional and cutting-edge disciplines. Mobile Apps and Web Analytics solutions merge well-established data analysis techniques with innovative technologies to build, model, and refine decision-making frameworks. This convergence allows for more comprehensive and actionable insights into both app performance and user behavior.

These solutions stand out due to their integration of behavioral and operational analytics, which track not only the technical performance of apps but also user interactions. By understanding how users engage with apps, businesses can optimize the user experience and adapt their offerings to meet evolving needs, leading to higher engagement and retention rates.

Another distinctive aspect is the focus on using collected data to continually enhance the user experience. The insights derived from analytics allow for ongoing adjustments to app design and functionality, ensuring apps remain engaging, responsive, and reliable, thus fostering long-term user loyalty and satisfaction.

The ability to make real-time adjustments based on analytics is a key feature of this market. Mobile Apps and Web Analytics solutions offer immediate insights into app performance and user activity, enabling businesses to quickly address issues, optimize operations, and make informed decisions to enhance the overall effectiveness of their mobile and web platforms.

Major Highlights of the Mobile Apps and Web Analytics Market

A major highlight of the market is the integration of both traditional and modern analytical disciplines. These solutions bring together time-tested data analysis methods and cutting-edge technologies, enabling businesses to build, align, and refine decision models that drive performance and strategic improvements.

The market is distinguished by its focus on combining behavioral and operational analytics. These tools provide deep insights into both app performance and user interactions, allowing businesses to monitor how their apps function and how users engage with them. This comprehensive data enables the continuous optimization of user experience and app efficiency.

A standout feature of Mobile Apps and Web Analytics is its ability to drive continuous improvements in user experience. The insights generated allow businesses to fine-tune app functionality in real time, ensuring that user needs are met, which in turn increases engagement, satisfaction, and loyalty.

The real-time decision-making capability of these analytics solutions is a key highlight. By providing instant feedback on app performance and user behavior, businesses can swiftly address issues, make data-driven adjustments, and optimize their operations to ensure that their apps remain reliable and engaging for users.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=139197732  

Top Companies in the Mobile Apps and Web Analytics Market

Major vendors in the global Mobile Apps and Web Analytics market are Microsoft (US), Google (US), Oracle (US), SAP (US), AWS, IBM (US), Teradata (US), Adobe (US), SAS Institute (US), Micro Focus (US), comScore (US), Salesforce (US), Splunk (US), Microstrategy (US), AT Internet (US), Webtrends (US), Tibco Software (US), Mixpanel (US), Upland Localytics (US), Amplitude Analytics (France), Qlik (US), Flurry (US), Cooldata (US), Countly (UK), Mobilebridge (Netherlands), Appsflyer (US), Uxcam (US), Incubasys (UAE), Datamatics Technologies (UAE), Alpha Byte (UAE), Celadon (UAE), Singular (Israel), Matomo (New Zealand), Plausible (Estonia), and Fathom (US).

IBM:

IBM is a multinational technology and consulting corporation that offers infrastructure, hosting, and consulting services. The company operates through five major business segments: cognitive solutions, global business services, technology services and cloud platforms, systems, and global financing. IBM offers mobile and web analytics solutions to set up and manage mobile and web so apps can access live and historical data. . It maintains strong partner relationships with leading IT providers such as AWS, Adobe, Cisco, KPMG, Kyndryl, Microsoft, Oracle, Salesforce, Samsung, SAP, ServiceNow, and Workday. The company has a presence in North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. In January 2022, IBM announced its acquisition of Envizi, a leading data and analytics software provider for environmental performance management.

ComScore:

ComScore is a leading company offering media and marketing measurement and analytics solutions. The company was founded in 1999 and is headquartered in Virginia, US. It offers a wide variety of audience and advertising analytics software solutions to its clients to understand audiences across platforms, such as mobile, desktops, and televisions. The company has a presence in more than 20 companies across the globe and caters to more than 2,500 clients in media, advertising, and marketing verticals, globally. In the mobile apps and web analytics market, comScore allows media buyers and sellers to quantify their multiscreen behavior and make business decisions.

Webtrends:

Webtrends is a leading provider of data analytics and personalization solutions. The company delivers actionable insights and helps boost customer engagement. It is an eminent provider of enterprise management and reporting solutions. Webtrends’ products are specifically designed to enable organizations to administer various internet-based systems throughout organizations, regardless of the geographic locations of servers supporting the systems. The company has a geographic presence in the US, EMEA, France, and Germany. It delivers extensive software-based analytics solutions in the field of web analytics, social media analytics, and mobile analytics under its product division called Webtrends Streams. These solutions assist businesses from numerous verticals, such as media, retail and consumer goods, healthcare and life sciences, travel and leisure, and telecommunication, in collecting, organizing, analyzing, and transforming raw customer information into useful data.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/mobile-apps-and-web-analytics-market-139197732.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mobile Apps and Web Analytics Market Size, Share, Future Trends, Growth Factors, Industry Analysis, Advance Technology And Forecast – 2027

HER2-Negative Breast Cancer Pipeline Insights, Treatment Drugs, Emerging Therapies and Companies 2024

DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in HER2-Negative Breast Cancer Research. Learn more about our innovative pipeline today! @ HER2-Negative Breast Cancer Pipeline Outlook

 

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report

  • In September 2024:- Borstkanker Onderzoek Groep– This is a multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
  • In September 2024:- RayzeBio Inc.- Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) Alone and in Combination with Pembrolizumab in Subjects with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates And/or Chemotherapy (TRACY-1)
  • In September 2024:- Hoffmann-La Roche- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer).
  • DelveInsight’s HER2-Negative Breast Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for HER2-Negative Breast Cancer treatment.
  • The leading HER2-Negative Breast Cancer Companies such as Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.
  • Promising HER2 Negative Breast Cancer Therapies such as Doxorubicin, Cyclophosphamide, Utidelone Combined with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and others.

 

Stay informed about the cutting-edge advancements in HER2-Negative Breast Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ HER2-Negative Breast Cancer Clinical Trials Assessment

 

HER2-Negative Breast Cancer Emerging Drugs

  • Giredestrant : Genentech

Giredestrant is a novel investigative small molecule that works as selective estrogen receptor degrader (SERD) by targeting the estrogen receptor (ER). The drug candidate is a new molecular entity (NME) which is administered through oral route. Preclinical studies suggest that Giredestrant is orally bioavailable and competitively inhibits the binding of estrogen to the ER. In preclinical models, Giredestrant has been shown to restrain the normally dynamic behavior of both wild-type and mutant ER, immobilizing the ER and attenuating the expression of its target genes. Currently, the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

  • Inavolisib : Genentech

Inavolisib is an investigational small molecule designed to selectively inhibit mutant PI3Kα. In preclinical models, the molecule showed potent selective inhibition of PI3Kα and has increased potency to mutant PI3K cells over wild type. It is less sensitive for the other three PI3K isoforms. Inavolisib binds to the ATP-binding site of PI3Kα, thereby blocking phosphorylation of PIP2 to PIP3 and preventing downstream signaling as shown in preclinical models. Moreover, inavolisib specifically degrades the mutant form of PI3Kα, resulting in reduction of pathway activity. Currently the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

  • CX-2009 : CytomX Therapeutics

CX-2009 (Praluzatamab ravtansine) is a conditionally activated antibody-drug conjugate (ADC) comprised of a CD166-directed humanized monoclonal antibody conjugated to the maytansinoid DM4, a tubulin inhibitor. Praluzatamab ravtansine utilizes CytomX Probody® platform technology, which incorporates a masking peptide to cover and block the cellular binding region of the antibody. Tethered to the antibody via a protease-cleavable linker, currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

  • H3B 6545 : H3 Biomedicine

H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer. H3B- 6545, a first-in-class small molecule selective estrogen receptor covalent antagonist (SERCA) demonstrates activity in tumor models that harbor wild-type or mutant ERα.4 H3B-6545 activity against ERα mutants resistant to standard therapy provides an opportunity to target a currently unmet medical need both as a single agent and in combination with other breast cancer therapies. Currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

  • RGT-419B : Regor Therapeutics

RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. Results from non-clinical studies showed that RGT-419B demonstrated full suppression of ER+ breast cancer cell proliferation with acquired resistance to CDK4/6 inhibitors. Additionally, RGT-419B’s tumor cell suppression was further augmented when combined with a selective estrogen receptor down-regulator or a PI3K signaling pathway inhibitor. Currently, the drug is in Phase I stage of its development for the treatment of HER2 negative breast cancer.

 

Learn more about HER2-Negative Breast Cancer Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ HER2-Negative Breast Cancer Unmet Needs

 

HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

HER2-Negative Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Discover the latest advancements in HER2-Negative Breast Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ HER2-Negative Breast Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the HER2-Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • HER2-Negative Breast Cancer Companies- Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.
  • HER2 Negative Breast Cancer Therapies- Doxorubicin, Cyclophosphamide, Utidelone Combined with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and others.
  • HER2-Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • HER2-Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of H HER2-Negative Breast Cancer Pipeline on our website @ HER2-Negative Breast Cancer Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. HER2 Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Giredestrant : Genentech
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CX-2009 : CytomX Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RGT-419B : Regor Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. HER2 Negative Breast Cancer Key Companies
  21. HER2 Negative Breast Cancer Key Products
  22. HER2 Negative Breast Cancer- Unmet Needs
  23. HER2 Negative Breast Cancer- Market Drivers and Barriers
  24. HER2 Negative Breast Cancer- Future Perspectives and Conclusion
  25. HER2 Negative Breast Cancer Analyst Views
  26. HER2 Negative Breast Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-Negative Breast Cancer Pipeline Insights, Treatment Drugs, Emerging Therapies and Companies 2024

EV Charging Equipment Market to Hit $46.13 Billion by 2029, 2X Growth in the Next 6 Years – Exclusive Research Report by Arizton

“EV Charging Equipment Market Research Report by Arizton”

According to Arizton’s latest research report, the EV charging equipment market is growing at a CAGR of 14.32% during 2023-2029.

    

Looking for More Information? Click: https://www.arizton.com/market-reports/ev-charging-equipment-market

  

Report Scope:    

Market Size (2029): $46.13 Billion        

Market Size (2023): $20.67 Billion        

CAGR (2023-2029): 14.32%   

Historic Year:  2020-2022            

Base Year: 2023            

Forecast Year: 2024-2029            

Market Segmentation: Product, End-Users, Components, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa    

    

Book the Free Sample Now: https://www.arizton.com/market-reports/ev-charging-equipment-market

  

As the world intensifies its efforts to combat climate change, the electric vehicle (EV) charging equipment market is experiencing significant growth. Governments across the globe are implementing stringent emission regulations and setting ambitious targets to promote EV adoption.

The European Union, for example, has committed to a remarkable 37.5% reduction in CO2 emissions from new cars by 2030 compared to 2021 levels. Similarly, pioneering nations like Norway and the Netherlands are leading the charge with plans to ban the sale of new internal combustion engine vehicles by 2025 and 2030, respectively.

These proactive regulatory frameworks are compelling automotive manufacturers to accelerate their EV production. As the number of electric vehicles on the road continues to rise, the demand for robust and extensive charging infrastructure is becoming increasingly critical.

This convergence of environmental policy and automotive innovation presents a unique opportunity for growth within the EV charging equipment market, as stakeholders work together to create a sustainable future.

 

Key Market Development in the Global EV Charging Equipment Market

  • In 2024, the EVBox group partnered with SMEG to supply 300 Troniq Modular fast charging stations to EVzen, boosting its presence in France and expanding its share of the European EV charging equipment market.
  • In 2024, ChargePoint, Inc. and LG Electronics have partnered to innovate EV charging, combining the company management software with LG’s hardware. This partnership enhances both companies’ positions in the EV charging market, leveraging their combined expertise for advanced infrastructure projects.

 

 

Key Company Profiles

  • ABB
  • Alfen N.V.
  • ChargePoint, Inc.
  • Delta Electronics, Inc.
  • Eaton
  • EVBox Group
  • Kempower
  • StarCharge
  • TELD New Energy Co. Ltd
  • Wallbox Chargers, S.L.
  • Aclara Technologies
  • Aeidth Technologies
  • AMPECO LTD
  • Blink Charging Co.
  • Bolt.Earth
  • bp pulse
  • ChargeHub
  • Chargemaster
  • chargeMOD
  • Delphi Technologies
  • Driivz
  • Efacec
  • Enel X Way
  • Enphase Energy
  • EVQ Point
  • GARO
  • Green Energy Wallet
  • IES Synergy
  • IOTECHA
  • Landis+Gyr
  • Leviton Manufacturing Co., Inc
  • Okaya EV Pvt. Ltd.
  • Pod Point
  • QuantumEV
  • Schneider Electric
  • Shanghai Xundao New Energy Technology Co., Ltd.
  • Sicon Chat Union Electric Co., Ltd.
  • Siemens
  • SimplyFuel Solutions
  • SYNOP
  • Tap Electric
  • Tesla
  • Titan Power
  • Tridens d.o.o.
  • Volttic EV Charging
  • Xuji Group Co., Ltd.

 

AC Chargers Dominate Global EV Charging Equipment Market in 2023

In 2023, the AC product segment leads the global EV charging equipment market, capturing the largest share of revenue. This dominance is attributed to the cost-effectiveness, seamless grid integration, and ongoing technological advancements associated with AC chargers. Their flexibility, especially for overnight home charging using off-peak electricity rates, enhances their appeal among EV owners, further boosting market growth.

AC chargers can be easily integrated into existing electrical grids, which is crucial as these grids adapt to meet the rising demand from electric vehicles. Additionally, this integration allows businesses and municipalities to expand charging networks without incurring significant upfront costs. Continuous improvements in charging technology, including faster charging speeds and more efficient systems, are expected to further drive demand for AC chargers in the coming years.

 

Market Segmentation

 

Product

  • AC
  • DC

 

End-Users

  • Residential
  • Commercial

 

Components

  • Hardware
  • Software

 

Geographical Overview

The demand for EV charging equipment is rapidly increasing worldwide, driven by technological innovations, supportive government policies, rising environmental awareness, and greater consumer adoption of electric vehicles (EVs). In North America, growing environmental consciousness and lower operational costs are fueling consumer demand for EVs, prompting automakers to expand their offerings and increasing the need for robust charging infrastructure. Utilities and private companies are actively investing in fast-charging networks, alleviating range anxiety for EV owners.

Europe leads in EV adoption and charging infrastructure, with the European Commission targeting 3.5 million charging points by 2030 to meet stringent carbon reduction goals. Countries like Norway, Germany, and the UK are implementing significant incentives to promote EV use.

The APAC region, particularly China, Japan, South Korea, and India, is also witnessing substantial growth. China’s government initiatives and subsidies are pivotal in driving EV adoption, while Japan and South Korea set ambitious targets for infrastructure development. In India, government schemes are furthering EV acceptance and infrastructure investment.

In Latin America, countries like Brazil and Mexico are beginning to invest in EV infrastructure, although adoption remains limited by costs. Meanwhile, the Middle East and Africa are emerging markets for EV charging, with the UAE and South Africa leading investment efforts.

As the prevalence of EVs increases and charging technology evolves, the demand for EV charging equipment is expected to rise, transforming the future of transportation and energy systems globally.

 

Geography

 

APAC

  • China
  • South Korea
  • Japan
  • India
  • Australia
  • Thailand
  • New Zealand

 

Europe

  • Netherlands
  • France
  • Germany
  • The U.K.
  • Italy
  • Belgium
  • Spain

 

North America

  • The U.S.
  • Canada

 

Latin America

  • Brazil
  • Mexico
  • Colombia

 

Middle East & Africa

  • South Africa
  • The UAE
  • Egypt

 

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4456

    

Key Questions Answered in the Report:    

What is the growth rate of the global EV charging equipment market?

How big is the global EV charging equipment market?

What are the significant trends in the EV charging equipment market?

Which region dominates the global EV charging equipment market share?

Who are the key players in the global EV charging equipment market?

  

Check Out Some of the Top Selling Research Reports:  

Automotive Electric Seats Market – Global Outlook & Forecast 2023-2028: The global automotive electric seats market was valued at USD 62 billion in 2022 and is expected to reach USD 85.62 billion by 2028, growing at a CAGR of 5.53%. Explore! https://www.arizton.com/market-reports/automotive-electric-seats-market

Electric Vehicle Battery Recycling Market – Global Outlook & Forecast 2023-2028

The electric vehicle battery recycling market size was valued at USD 8.20 billion in 2022 and is expected to reach USD 20.06 billion by 2028, growing at a CAGR of 16.08% during the forecast period. Explore! https://www.arizton.com/market-reports/electric-vehicle-battery-recycling-market

 

Why Arizton?                                             

100% Customer Satisfaction                                             

24×7 availability – we are always there when you need us                                             

200+ Fortune 500 Companies trust Arizton’s report                                             

80% of our reports are exclusive and first in the industry                                             

100% more data and analysis                                             

1500+ reports published till date                           

                

Post-Purchase Benefit                                         

  • 1hr of free analyst discussion                                         
  • 10% off on customization                      

               

About Us:                                                                                  

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707  
Country: United States
Website: https://www.arizton.com/market-reports/ev-charging-equipment-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EV Charging Equipment Market to Hit $46.13 Billion by 2029, 2X Growth in the Next 6 Years – Exclusive Research Report by Arizton